Internal tandem duplications and tyrosine kinase mutations in the fms-like tyrosine kinase 3
(FLT3) receptor can occur in acute myeloid leukemia (AML) and portend a poor prognosis …

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients
with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by …

Mutations in the fms-like tyrosine kinase 3 (FLT3) gene are detected in approximately one-
third of patients with newly diagnosed acute myeloid leukemia (AML). These consist of the …

FLT3 inhibition as a targeted therapy for acute myeloid leuk... : Current Opinion in Oncology
FLT3 inhibition as a targeted therapy for acute myeloid leukemia : Current Opinion in Oncology …

The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating
survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is …

Despite recent modest improvements in the chemotherapy regimens used to treat acute
myeloid leukemia (AML), many patients diagnosed with AML ultimately die of the disease …

Acute myeloid leukemia (AML) is a highly heterogeneous disease. Mutation with internal
tandem duplication of fms-like tyrosine kinase-3 (FLT3-ITD) is one of the two most common …

Introduction: Acute myeloblastic leukemia (AML) is the most frequent type of acute leukemia
in adults with an incidence of 4.2 cases per 100,000 inhabitants and poor 5-year survival …

Abstract Learning Objectives After completing this course, the reader will be able to:
Incorporate FLT3 mutational status into the initial diagnostic evaluation of AML to acquire …

Background FMS-like tyrosine kinase 3 (FLT3) is the most frequent mutation in AML. With
two FLT3 inhibitors recently approved by the FDA (midostaurin and gilteritinib), there is a …